Review



wild type wt full length polq cdna  (New England Biolabs)


Bioz Verified Symbol New England Biolabs is a verified supplier
Bioz Manufacturer Symbol New England Biolabs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    New England Biolabs wild type wt full length polq cdna
    a . A schematic shows how the PARPi resistant clones R1-R4 were generated. b . A Western blot of WT and BRCA1 −/− RPE1 cells and the PARPi resistant clones, using an anti-BRCA1 antibody (Millipore #OP92). No BRCA1 reversion was observed in the clones. c-d. NVB sensitivity of WT RPE1, BRCA1 −/− RPE1, and PARPi-resistant BRCA1 −/− clones (R1-R4). R1 was selected by olaparib and R2-R4 were selected by Niraparib. R1 and R2 were tested in clonogenic survival assays (12–14 days) (c) . R3 and R4 were tested in CellTiter-Glo cell viability assay (6 days) ( d ). Data are mean ± SEM, n = 3 independent cultures. e . <t>POLQ</t> expression at mRNA level and protein level in WT RPE1, BRCA1 −/− RPE1, and PARPi-resistant BRCA1 −/− clones (R1-R4). POLQ mRNA was measured by qRT-PCR and normalized to beta-Actin (ACTB). Mean ± SD of n=4 independent cultures. f . POLQ expression at mRNA level in parental (P), PARPi resistant (R), and empty vector (+EV) or <t>BRCA1-cDNA</t> (+BR1) complemented MDA-MB-436 cells. Mean ± SD of n=4 independent cultures. g . POLQ expression at mRNA level in PDX models DF53, DF83 and DF149. Mean of 4 technical replicates for each PDX model are shown. h . Olaparib sensitivity of CAPAN1 (BRCA2 mutated) and CAPAN1-CR cells (BRCA2 CRISPR edited back to wild type) in clonogenic survival assays. i . NVB sensitivity of CAPAN1 and CAPAN1-CR cells in clonogenic survival assays. Mean of n=2 independent experiments are shown in h and i . Statistical analysis in h and i were paired t-test, * p < 0.05, j . The expression levels of POLQ in CAPAN1 and CAPAN1-CR cells, analyzed by Western blotting.
    Wild Type Wt Full Length Polq Cdna, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/wild+type+wt+full+length+polq+cdna/pmc08224818-297-0-21
    Average 86 stars, based on 1 article reviews
    wild type wt full length polq cdna - by Bioz Stars, 2026-10
    86/100 stars

    Images

    1) Product Images from "A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors"

    Article Title: A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors

    Journal: Nature cancer

    doi: 10.1038/s43018-021-00203-x

    a . A schematic shows how the PARPi resistant clones R1-R4 were generated. b . A Western blot of WT and BRCA1 −/− RPE1 cells and the PARPi resistant clones, using an anti-BRCA1 antibody (Millipore #OP92). No BRCA1 reversion was observed in the clones. c-d. NVB sensitivity of WT RPE1, BRCA1 −/− RPE1, and PARPi-resistant BRCA1 −/− clones (R1-R4). R1 was selected by olaparib and R2-R4 were selected by Niraparib. R1 and R2 were tested in clonogenic survival assays (12–14 days) (c) . R3 and R4 were tested in CellTiter-Glo cell viability assay (6 days) ( d ). Data are mean ± SEM, n = 3 independent cultures. e . POLQ expression at mRNA level and protein level in WT RPE1, BRCA1 −/− RPE1, and PARPi-resistant BRCA1 −/− clones (R1-R4). POLQ mRNA was measured by qRT-PCR and normalized to beta-Actin (ACTB). Mean ± SD of n=4 independent cultures. f . POLQ expression at mRNA level in parental (P), PARPi resistant (R), and empty vector (+EV) or BRCA1-cDNA (+BR1) complemented MDA-MB-436 cells. Mean ± SD of n=4 independent cultures. g . POLQ expression at mRNA level in PDX models DF53, DF83 and DF149. Mean of 4 technical replicates for each PDX model are shown. h . Olaparib sensitivity of CAPAN1 (BRCA2 mutated) and CAPAN1-CR cells (BRCA2 CRISPR edited back to wild type) in clonogenic survival assays. i . NVB sensitivity of CAPAN1 and CAPAN1-CR cells in clonogenic survival assays. Mean of n=2 independent experiments are shown in h and i . Statistical analysis in h and i were paired t-test, * p < 0.05, j . The expression levels of POLQ in CAPAN1 and CAPAN1-CR cells, analyzed by Western blotting.
    Figure Legend Snippet: a . A schematic shows how the PARPi resistant clones R1-R4 were generated. b . A Western blot of WT and BRCA1 −/− RPE1 cells and the PARPi resistant clones, using an anti-BRCA1 antibody (Millipore #OP92). No BRCA1 reversion was observed in the clones. c-d. NVB sensitivity of WT RPE1, BRCA1 −/− RPE1, and PARPi-resistant BRCA1 −/− clones (R1-R4). R1 was selected by olaparib and R2-R4 were selected by Niraparib. R1 and R2 were tested in clonogenic survival assays (12–14 days) (c) . R3 and R4 were tested in CellTiter-Glo cell viability assay (6 days) ( d ). Data are mean ± SEM, n = 3 independent cultures. e . POLQ expression at mRNA level and protein level in WT RPE1, BRCA1 −/− RPE1, and PARPi-resistant BRCA1 −/− clones (R1-R4). POLQ mRNA was measured by qRT-PCR and normalized to beta-Actin (ACTB). Mean ± SD of n=4 independent cultures. f . POLQ expression at mRNA level in parental (P), PARPi resistant (R), and empty vector (+EV) or BRCA1-cDNA (+BR1) complemented MDA-MB-436 cells. Mean ± SD of n=4 independent cultures. g . POLQ expression at mRNA level in PDX models DF53, DF83 and DF149. Mean of 4 technical replicates for each PDX model are shown. h . Olaparib sensitivity of CAPAN1 (BRCA2 mutated) and CAPAN1-CR cells (BRCA2 CRISPR edited back to wild type) in clonogenic survival assays. i . NVB sensitivity of CAPAN1 and CAPAN1-CR cells in clonogenic survival assays. Mean of n=2 independent experiments are shown in h and i . Statistical analysis in h and i were paired t-test, * p < 0.05, j . The expression levels of POLQ in CAPAN1 and CAPAN1-CR cells, analyzed by Western blotting.

    Techniques Used: Clone Assay, Generated, Western Blot, Viability Assay, Expressing, Quantitative RT-PCR, Plasmid Preparation, CRISPR

    a-b , Olaparib ( a ) and NVB ( b ) sensitivity of UWB1.289 and a PARPi resistant UWB1.289 clone (UWB1.289-YSR12) in CellTiter-Glo assays. Data shown are mean ± SD, n = 4 biological replicates. c . Western blot analysis of POLQ expression levels in in WT and BRCA1 −/− RPE1 cells and the PARPi resistant BRCA1 −/− clones. d. Olaparib sensitivity of PEO1 (BRCA2 mutated) and PEO4 cells (BRCA2 restored). e . NVB sensitivity of PEO1 and PEO4 cells. Data shown in d and e are Mean ± SD, n= 3 biological replicates. f . A Western blot shows POLQ expression in BRCA2-decient cells lines (PEO1) and their counterparts with BRCA2 reverted to wild type (PEO4).
    Figure Legend Snippet: a-b , Olaparib ( a ) and NVB ( b ) sensitivity of UWB1.289 and a PARPi resistant UWB1.289 clone (UWB1.289-YSR12) in CellTiter-Glo assays. Data shown are mean ± SD, n = 4 biological replicates. c . Western blot analysis of POLQ expression levels in in WT and BRCA1 −/− RPE1 cells and the PARPi resistant BRCA1 −/− clones. d. Olaparib sensitivity of PEO1 (BRCA2 mutated) and PEO4 cells (BRCA2 restored). e . NVB sensitivity of PEO1 and PEO4 cells. Data shown in d and e are Mean ± SD, n= 3 biological replicates. f . A Western blot shows POLQ expression in BRCA2-decient cells lines (PEO1) and their counterparts with BRCA2 reverted to wild type (PEO4).

    Techniques Used: Western Blot, Expressing, Clone Assay

    Related Articles

    Polymerase Chain Reaction:

    Article Title: A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors
    Article Snippet: Western blots were collected using Odyssey Infrared Imagers (Li-Cor), and analyzed using Image Studio Lite. .. Wild type (WT) full length POLQ cDNA was assembled by PCR with a FLAG-P2A-BLAST cassette and subsequently cloned by Gibson assembly (New England BioLabs, #E2611L) in the PiggyBac PBCAG-eGFP vector (Addgene #40973) using BsrGI and SbfI sites to obtain the PiggyBac-eGFP-POLQ-FLAG-P2A-BLAST vector (referred here as GFP-Polθ WT). ..

    Clone Assay:

    Article Title: A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors
    Article Snippet: Western blots were collected using Odyssey Infrared Imagers (Li-Cor), and analyzed using Image Studio Lite. .. Wild type (WT) full length POLQ cDNA was assembled by PCR with a FLAG-P2A-BLAST cassette and subsequently cloned by Gibson assembly (New England BioLabs, #E2611L) in the PiggyBac PBCAG-eGFP vector (Addgene #40973) using BsrGI and SbfI sites to obtain the PiggyBac-eGFP-POLQ-FLAG-P2A-BLAST vector (referred here as GFP-Polθ WT). ..

    Plasmid Preparation:

    Article Title: A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors
    Article Snippet: Western blots were collected using Odyssey Infrared Imagers (Li-Cor), and analyzed using Image Studio Lite. .. Wild type (WT) full length POLQ cDNA was assembled by PCR with a FLAG-P2A-BLAST cassette and subsequently cloned by Gibson assembly (New England BioLabs, #E2611L) in the PiggyBac PBCAG-eGFP vector (Addgene #40973) using BsrGI and SbfI sites to obtain the PiggyBac-eGFP-POLQ-FLAG-P2A-BLAST vector (referred here as GFP-Polθ WT). ..



    Similar Products

    wild type wt full length polq cdna  (New England Biolabs)
    86
    New England Biolabs wild type wt full length polq cdna
    a . A schematic shows how the PARPi resistant clones R1-R4 were generated. b . A Western blot of WT and BRCA1 −/− RPE1 cells and the PARPi resistant clones, using an anti-BRCA1 antibody (Millipore #OP92). No BRCA1 reversion was observed in the clones. c-d. NVB sensitivity of WT RPE1, BRCA1 −/− RPE1, and PARPi-resistant BRCA1 −/− clones (R1-R4). R1 was selected by olaparib and R2-R4 were selected by Niraparib. R1 and R2 were tested in clonogenic survival assays (12–14 days) (c) . R3 and R4 were tested in CellTiter-Glo cell viability assay (6 days) ( d ). Data are mean ± SEM, n = 3 independent cultures. e . <t>POLQ</t> expression at mRNA level and protein level in WT RPE1, BRCA1 −/− RPE1, and PARPi-resistant BRCA1 −/− clones (R1-R4). POLQ mRNA was measured by qRT-PCR and normalized to beta-Actin (ACTB). Mean ± SD of n=4 independent cultures. f . POLQ expression at mRNA level in parental (P), PARPi resistant (R), and empty vector (+EV) or <t>BRCA1-cDNA</t> (+BR1) complemented MDA-MB-436 cells. Mean ± SD of n=4 independent cultures. g . POLQ expression at mRNA level in PDX models DF53, DF83 and DF149. Mean of 4 technical replicates for each PDX model are shown. h . Olaparib sensitivity of CAPAN1 (BRCA2 mutated) and CAPAN1-CR cells (BRCA2 CRISPR edited back to wild type) in clonogenic survival assays. i . NVB sensitivity of CAPAN1 and CAPAN1-CR cells in clonogenic survival assays. Mean of n=2 independent experiments are shown in h and i . Statistical analysis in h and i were paired t-test, * p < 0.05, j . The expression levels of POLQ in CAPAN1 and CAPAN1-CR cells, analyzed by Western blotting.
    Wild Type Wt Full Length Polq Cdna, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/wild+type+wt+full+length+polq+cdna/pmc08224818-297-0-21
    Average 86 stars, based on 1 article reviews
    wild type wt full length polq cdna - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    a . A schematic shows how the PARPi resistant clones R1-R4 were generated. b . A Western blot of WT and BRCA1 −/− RPE1 cells and the PARPi resistant clones, using an anti-BRCA1 antibody (Millipore #OP92). No BRCA1 reversion was observed in the clones. c-d. NVB sensitivity of WT RPE1, BRCA1 −/− RPE1, and PARPi-resistant BRCA1 −/− clones (R1-R4). R1 was selected by olaparib and R2-R4 were selected by Niraparib. R1 and R2 were tested in clonogenic survival assays (12–14 days) (c) . R3 and R4 were tested in CellTiter-Glo cell viability assay (6 days) ( d ). Data are mean ± SEM, n = 3 independent cultures. e . POLQ expression at mRNA level and protein level in WT RPE1, BRCA1 −/− RPE1, and PARPi-resistant BRCA1 −/− clones (R1-R4). POLQ mRNA was measured by qRT-PCR and normalized to beta-Actin (ACTB). Mean ± SD of n=4 independent cultures. f . POLQ expression at mRNA level in parental (P), PARPi resistant (R), and empty vector (+EV) or BRCA1-cDNA (+BR1) complemented MDA-MB-436 cells. Mean ± SD of n=4 independent cultures. g . POLQ expression at mRNA level in PDX models DF53, DF83 and DF149. Mean of 4 technical replicates for each PDX model are shown. h . Olaparib sensitivity of CAPAN1 (BRCA2 mutated) and CAPAN1-CR cells (BRCA2 CRISPR edited back to wild type) in clonogenic survival assays. i . NVB sensitivity of CAPAN1 and CAPAN1-CR cells in clonogenic survival assays. Mean of n=2 independent experiments are shown in h and i . Statistical analysis in h and i were paired t-test, * p < 0.05, j . The expression levels of POLQ in CAPAN1 and CAPAN1-CR cells, analyzed by Western blotting.

    Journal: Nature cancer

    Article Title: A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors

    doi: 10.1038/s43018-021-00203-x

    Figure Lengend Snippet: a . A schematic shows how the PARPi resistant clones R1-R4 were generated. b . A Western blot of WT and BRCA1 −/− RPE1 cells and the PARPi resistant clones, using an anti-BRCA1 antibody (Millipore #OP92). No BRCA1 reversion was observed in the clones. c-d. NVB sensitivity of WT RPE1, BRCA1 −/− RPE1, and PARPi-resistant BRCA1 −/− clones (R1-R4). R1 was selected by olaparib and R2-R4 were selected by Niraparib. R1 and R2 were tested in clonogenic survival assays (12–14 days) (c) . R3 and R4 were tested in CellTiter-Glo cell viability assay (6 days) ( d ). Data are mean ± SEM, n = 3 independent cultures. e . POLQ expression at mRNA level and protein level in WT RPE1, BRCA1 −/− RPE1, and PARPi-resistant BRCA1 −/− clones (R1-R4). POLQ mRNA was measured by qRT-PCR and normalized to beta-Actin (ACTB). Mean ± SD of n=4 independent cultures. f . POLQ expression at mRNA level in parental (P), PARPi resistant (R), and empty vector (+EV) or BRCA1-cDNA (+BR1) complemented MDA-MB-436 cells. Mean ± SD of n=4 independent cultures. g . POLQ expression at mRNA level in PDX models DF53, DF83 and DF149. Mean of 4 technical replicates for each PDX model are shown. h . Olaparib sensitivity of CAPAN1 (BRCA2 mutated) and CAPAN1-CR cells (BRCA2 CRISPR edited back to wild type) in clonogenic survival assays. i . NVB sensitivity of CAPAN1 and CAPAN1-CR cells in clonogenic survival assays. Mean of n=2 independent experiments are shown in h and i . Statistical analysis in h and i were paired t-test, * p < 0.05, j . The expression levels of POLQ in CAPAN1 and CAPAN1-CR cells, analyzed by Western blotting.

    Article Snippet: Wild type (WT) full length POLQ cDNA was assembled by PCR with a FLAG-P2A-BLAST cassette and subsequently cloned by Gibson assembly (New England BioLabs, #E2611L) in the PiggyBac PBCAG-eGFP vector (Addgene #40973) using BsrGI and SbfI sites to obtain the PiggyBac-eGFP-POLQ-FLAG-P2A-BLAST vector (referred here as GFP-Polθ WT).

    Techniques: Clone Assay, Generated, Western Blot, Viability Assay, Expressing, Quantitative RT-PCR, Plasmid Preparation, CRISPR

    a-b , Olaparib ( a ) and NVB ( b ) sensitivity of UWB1.289 and a PARPi resistant UWB1.289 clone (UWB1.289-YSR12) in CellTiter-Glo assays. Data shown are mean ± SD, n = 4 biological replicates. c . Western blot analysis of POLQ expression levels in in WT and BRCA1 −/− RPE1 cells and the PARPi resistant BRCA1 −/− clones. d. Olaparib sensitivity of PEO1 (BRCA2 mutated) and PEO4 cells (BRCA2 restored). e . NVB sensitivity of PEO1 and PEO4 cells. Data shown in d and e are Mean ± SD, n= 3 biological replicates. f . A Western blot shows POLQ expression in BRCA2-decient cells lines (PEO1) and their counterparts with BRCA2 reverted to wild type (PEO4).

    Journal: Nature cancer

    Article Title: A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors

    doi: 10.1038/s43018-021-00203-x

    Figure Lengend Snippet: a-b , Olaparib ( a ) and NVB ( b ) sensitivity of UWB1.289 and a PARPi resistant UWB1.289 clone (UWB1.289-YSR12) in CellTiter-Glo assays. Data shown are mean ± SD, n = 4 biological replicates. c . Western blot analysis of POLQ expression levels in in WT and BRCA1 −/− RPE1 cells and the PARPi resistant BRCA1 −/− clones. d. Olaparib sensitivity of PEO1 (BRCA2 mutated) and PEO4 cells (BRCA2 restored). e . NVB sensitivity of PEO1 and PEO4 cells. Data shown in d and e are Mean ± SD, n= 3 biological replicates. f . A Western blot shows POLQ expression in BRCA2-decient cells lines (PEO1) and their counterparts with BRCA2 reverted to wild type (PEO4).

    Article Snippet: Wild type (WT) full length POLQ cDNA was assembled by PCR with a FLAG-P2A-BLAST cassette and subsequently cloned by Gibson assembly (New England BioLabs, #E2611L) in the PiggyBac PBCAG-eGFP vector (Addgene #40973) using BsrGI and SbfI sites to obtain the PiggyBac-eGFP-POLQ-FLAG-P2A-BLAST vector (referred here as GFP-Polθ WT).

    Techniques: Western Blot, Expressing, Clone Assay